VIDEO INTERVIEW – Metabolic health does matter: lessons from the COVID-19 pandemic

Overview

Since its identification in late 2019 and subsequent global spread, SARS-CoV-2 infection has caused millions of deaths and people with underlying cardiometabolic conditions have experienced poorer outcomes than those with good metabolic health. Indeed, obesity, diabetes and hypertension are the most common comorbidities associated with morbidity and mortality among patients affected by COVID-19. The joint occurrence of a pre-existing underlying diabesity pandemic with the acute COVID-19 pandemic has accentuated the already heavy burden of cardiometabolic conditions (diabetes in particular) for millions of people worldwide. Furthermore, a reciprocal interaction between COVID-19 and glucose metabolism has been suggested, with SARS-CoV-2 infection itself potentially being deleterious for metabolic health. In this video interview, Professor Antonio Ceriello, a world renown key opinion leader in this field, will discuss the complex combination of COVID-19 and cardiometabolic disease.

Learning Objectives

By participating in this on-line activity, attendees will:

  1. Learn about the relationships between COVID-19 infection and metabolic disorders
  2. Understand the direct and indirect effects of the COVID-19 pandemic on people with diabesity
  3. Receive guidance to tackle the possible long-term metabolic consequences of COVID-19

Target audience

This activity is designed for Diabetologists, Endocrinologists, General Practitioners, Internists and specialists involved in the diagnosis and management of patients with diabetes.

 

Overview

Since its identification in late 2019 and subsequent global spread, SARS-CoV-2 infection has caused millions of deaths and people with underlying cardiometabolic conditions have experienced poorer outcomes than those with good metabolic health. Indeed, obesity, diabetes and hypertension are the most common comorbidities associated with morbidity and mortality among patients affected by COVID-19. The joint occurrence of a pre-existing underlying diabesity pandemic with the acute COVID-19 pandemic has accentuated the already heavy burden of cardiometabolic conditions (diabetes in particular) for millions of people worldwide. Furthermore, a reciprocal interaction between COVID-19 and glucose metabolism has been suggested, with SARS-CoV-2 infection itself potentially being deleterious for metabolic health. In this video interview, Professor Antonio Ceriello, a world renown key opinion leader in this field, will discuss the complex combination of COVID-19 and cardiometabolic disease.

Learning Objectives

By participating in this on-line activity, attendees will:

  1. Learn about the relationships between COVID-19 infection and metabolic disorders
  2. Understand the direct and indirect effects of the COVID-19 pandemic on people with diabesity
  3. Receive guidance to tackle the possible long-term metabolic consequences of COVID-19

Target audience

This activity is designed for Diabetologists, Endocrinologists, General Practitioners, Internists and specialists involved in the diagnosis and management of patients with diabetes.

 

Faculty

Antonio Ceriello
Head of the Research Diabetes Department
IRCCS MultiMedica
Milan, Italy

Biography

Antonio Ceriello is Head of the Diabetes Research Department of the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Milan, Italy. He has published widely in the field of diabetes, with over 500 original peer-reviewed papers published. He has chaired the International Diabetes Federation (IDF) committee producing guidelines for the management of postmeal glucose and is currently President of the European Association for the Study of Diabetes (EASD) study group on Diabetes and Cardiovascular Diseases. He is a member of the board for the development of the 2019 European Society of Cardiology (ESC) guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, and has served as a referee for the European Commission for the 2017 grant program for diabetes (HORIZON 2020 Program). In addition, Professor Ceriello served as Associate Editor of Diabetes Care from 2003 to 2011, Associate Editor of Diabetic Medicine from 2005 to 2016, and since July 2016, has been Editor-In-Chief of Diabetes Research and Clinical Practice, the official journal of the IDF and is currently in the Editorial Board of Cardiovascular Diabetology. Professor Ceriello is the winner of the 2004 EASD Camillo Golgi Prize and the 2017 Hellmut Mehnert Award from the IDF.

Faculty Disclosure

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Antonio Ceriello        Declared no potential conflict of interest

Release: 30 April 2021

All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.

This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

Copyright 2021 Scientific Seminars International Foundation